PD-1:PD-L1/L2/ & PD-L1: B7-1 Screening

BPS provides PD-1 biochemical and cell-based screening and profiling services. Biochemical screening services provide a great initial screen to find small molecules or biologics that prevent PD-1 from binding to its ligands; PD-L1, PD-L2, and B7-1. Then, the most promising hits can be further screened in our PD-1 reporter cell-based assay which offers a functional readout of the result (agonistic vs antagonistic) on PD-1 signaling. Trust us to provide you with high quality data with fast turnaround time. Our team of experts along with our broad services portfolio makes it easy to:

Screen for inhibitors/targets using our PD-1 assays

Select from IC50 determination and single point concentrations

Receive data within days of compound submission

Perform follow-up studies using the same soluble receptors manufactured in-house

Get questions answered or project guidance in a time-efficient manner

Contact BPS today to find out more about how we can assist you in your PD-1 related research.

This reporter based PD-1 cell based assay provides a tool for PD-1 drug screening and characterization that complements BPS' PD-1 biochemical screens.

Background:

Programmed cell death protein 1, or PD-1, is a protein which helps to regulate the immune system. PD-1 can bind to either PD-L1 or PD-L2 and as a result, inhibits T cell activation and other pro-inflammatory processes. This inhibition is accomplished through increasing apoptosis of T-cells and preventing apoptosis of suppressor T cells. PD-1 ligands are often over expressed in various types of cancer. Overexpression of PD-1 ligands helps cancer cells evade the immune system. As a result, PD-1 inhibitors have become an important target in immuno oncology.

In September of 2014, the first PD-1 antagonistic antibody, pembrolizumab (KeytrudaTM, Merck) was approved for the treatment of advanced melanoma under the FDA Fast Track Development Program[1] . In December of that same year, yet another PD-1 antagonistic antibody, nivolumab (OpdivoTM, Bristol-Myers Squibb) was approved for advanced melanoma[2] . Since their approval, PD-1 neutralizing antibodies have resulted in unprecedented response and survival rates in previously untreatable cancers. In addition to PD-1 neutralizing antibodies, the FDA recently approved the anti-PD-L1 antibody, atezolizumab (TecentriqTM, Roche) for the treatment locally advanced or metastatic urothelial carcinoma (mUC [3]).

BPS Bioscience offers many different types of PD-1 assay kits for screening inhibitors of PD-1:PD-L1 or PD-L2 interaction: